section name header

Evidence summaries

Cabergoline for Levodopa-Induced Complications in Parkinson's Disease

Cabergoline appears to be useful in reducing the dose of levodopa and in modestly improving motor impairment and disability. Level of evidence: "B"

A Cochrane review [Abstract] 1 included 3 studies with a total of 268 subjects. The reduction of 1.14 hours (WMD; 95% CI -0.06 to 2.33) in of time in favour of dyskinesia was not statistically significant. A small but statistically significant advantage of cabergoline (mean doses ranging from 2.64 to 5.4 mg/d) over placebo was seen in one study in UPDRS ADL score and UPDRS motor score. Levodopa dose reduction was significantly greater with caberboline (WMD 149.6 mg/d, 95% CI 94.1 to 205.1). There was a trend towards fewer withdrawals from cabergoline.

Comment: The quality of evidence is downgraded by sparse data.

    References

    • Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001;(1):CD001518. [PubMed]

Primary/Secondary Keywords